The 16,757 Shares of Pfizer Inc. (PFE) are sold by Congress Asset Management Co. MA

The 16,757 Shares of Pfizer Inc. (PFE) are sold by Congress Asset Management Co. MA

Congress Asset Management Co. MA lowered its stake in Pfizer Inc. (NYSE:PFE) by 57.2% during the second quarter, Holdings Channel reports. The institutional investor owned 12,540 shares of the biopharmaceutical company’s stock after selling 16,757 shares during the period. Congress Asset Management Co. MA’s holdings in Pfizer were worth $442,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Sigma Planning Corp increased its stake in shares of Pfizer by 9.9% in the first quarter. Sigma Planning Corp now owns 88,504 shares of the biopharmaceutical company’s stock valued at $2,623,000 after buying an additional 7,972 shares in the last quarter. Private Trust Co. NA increased its stake in Pfizer by 2.5% in the first quarter. Private Trust Co. NA now owns 114,956 shares of the biopharmaceutical company’s stock worth $3,406,000 after buying an additional 2,776 shares during the period. Traynor Capital Management Inc. increased its stake in Pfizer by 0.9% in the first quarter. Traynor Capital Management Inc. now owns 27,790 shares of the biopharmaceutical company’s stock worth $823,000 after buying an additional 254 shares during the period. Rhenman & Partners Asset Management AB increased its stake in Pfizer by 8.4% in the first quarter. Rhenman & Partners Asset Management AB now owns 475,000 shares of the biopharmaceutical company’s stock worth $14,079,000 after buying an additional 37,000 shares during the period. Finally, V Wealth Management LLC acquired a new stake in Pfizer during the first quarter worth approximately $272,000. 69.66% of the stock is owned by hedge funds and other institutional investors.

Pfizer Inc. (NYSE:PFE) traded down 0.97% during trading on Thursday, reaching $32.75. The company had a trading volume of 10,188,806 shares. The stock has a 50 day moving average of $34.14 and a 200-day moving average of $34.26. The company has a market capitalization of $198.65 billion, a P/E ratio of 29.03 and a beta of 0.86. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the firm posted $0.56 EPS. The business’s revenue was up 10.9% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post $2.46 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.63%. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.

PFE has been the subject of a number of recent analyst reports. Vetr raised Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 target price for the company in a report on Monday, June 27th. Deutsche Bank AG reissued a “buy” rating and issued a $44.00 target price on shares of Pfizer in a report on Thursday, August 18th. Credit Suisse Group AG reissued an “outperform” rating and issued a $40.00 target price on shares of Pfizer in a report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 target price on Pfizer and gave the company a “buy” rating in a report on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 target price on Pfizer and gave the company a “buy” rating in a report on Thursday, July 14th. Eleven research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $38.66.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Related posts

Leave a Comment